A Non-interventional Registry for Patients With Hepatitis B Virus Infection

In order to tackle the unmet needs in chronic HBV infection, a consortium of clinical partners has gathered to establish a registry for patients with hepatitis B mono- and co-infections. The partners will build up a European-wide registry to be able to stratify patients for upcoming clinical trials. Extensive analyses of virus and host-specific parameters are to be carried out from these patients. The knowledge gained thereby should contribute to a better understanding of the HBV control and enable patient stratification with regard to immunomodulatory therapies. Furthermore, hepatitis B patients are to be identified who are willing to participate in future studies to investigate immunotherapies to cure HBV infections (e.g. therapeutic vaccines).

Inclusion Criteria: * Hepatitis B Virus Infection TherVacB sub-cohort: * confirmed chronic hepatitis B virus infection: HBsAg positive for at least 1 year prior inclusion * HBeAg status documented for at least 6 months Exclusion Criteria: TherVacB sub-cohort: * age \>70 years * co-infection with HIV, HCV (RNA positive), * clinically relevant concomitant liver diseases (ALD, NASH, Haemochromatosis, Autoimmune hepatitis, AT1, Wilson's disease, primary biliary cirrhosis etc.) * significant comorbidities (e.g. malignancies) * immunosuppressive treatment (\> 40 mg Cortisol- equivalent) * liver cirrhosis (judged clinically or based on ultrasound/transient elastography) * History of hepatocellular carcinoma